This year’s first approved drugs, thrombocytopenic purpura antidiabetics

Although decided as ‘non-benefit’ due to unclear cost-effectiveness last year, treatments which will stably receive the benefit through reevaluation were revealed for this year.

According to the Drug Registration Division of the Health Insurance Review & Assessment Service, Kyowa Hakko Kirin Korea’s Romiplate(romiplostim) and ‘Nplate+(romiplostim)’ and GlaxoSmithKline’s ‘Revolade(eltrombopag)’...